Lv7
4975 积分 2021-03-15 加入
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
14天前
已完结
Ianalumab plus Eltrombopag in Immune Thrombocytopenia
14天前
已完结
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
15天前
已完结
Anti–CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE
15天前
已完结
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
15天前
已完结
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia
15天前
已完结
Refractory immune thrombocytopenia in adults: Towards a new definition
15天前
已完结
Long-term follow-up outcomes in congenital thrombotic thrombocytopenic purpura
17天前
已关闭
Recombinant ADAMTS13 in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
17天前
已关闭
TTP and pregnancy
17天前
已完结
皖公网安备34019202002308
